GlassScriptPhysician profile
Ellendale Gabbert
NPI 1134337017
$5,028.31
in general payments reported to CMS, 2019-2025
25 companies · $680 in 2025
The $680 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,347 · 2022: $1,241 · 2023: $1,132 · 2024: $628 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,375 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,375.25 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $731.53 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $669.83 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $642.87 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $487.82 | 2021-2023 | Farxiga, Brilinta |
| Pfizer INC. | $350.67 | 2022-2025 | |
| Amgen INC. | $251.17 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $214.53 | 2022-2025 | Camzyos, Eliquis |
| Abiomed | $212.43 | 2022-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $177.74 | 2022-2025 | Lifevest |
| Amarin Pharma, INC. | $173.49 | 2021 | |
| Janssen Pharmaceuticals, INC | $144.16 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.86 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $135.59 | 2022-2025 | Watchman Flx, Watchman |
| Cleerly, INC. | $135.36 | 2023-2025 | Cleerly Labs, Cleerly Ischemia |
| Actelion Pharmaceuticals US, INC. | $129.25 | 2023 | Opsumit, Uptravi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $104.48 | 2022 | |
| Scpharmaceuticals INC. | $49.85 | 2024-2025 | |
| Abbott Laboratories | $49.22 | 2021-2024 | Cardiomems |
| Atricure, INC. | $46.96 | 2024 | |
| Sanofi-Aventis U.S. LLC | $46.88 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $39.16 | 2021-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $35.07 | 2023 | Inpefa |
| Novo Nordisk INC | $30.58 | 2024-2025 | Ozempic, Wegovy |
| Silk Road Medical, INC. | $14.00 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Kiniksa Pharmaceuticals International, Plc | $13.81 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellendale Gabbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.